The Application of FePt@mSiO2-Polydopamine Core-Shell Nanoparticles as Multimodality-imaging and Therapeutic Agent

• Main Authors: Yu-Wei Chen, 陳毓為
• Other Authors: Pi-Tai Chou
• Format: Others
• Language: en_US
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/2er2xp

碩士 === 國立臺灣大學 === 化學研究所 === 105 === Multimodality-imaging strategies have been intensively developed in recent years due to the advantage of providing complementary information in preclinical research and early stage diagnosis. However, the develop of multimodality system is usually time-consuming and still remain challenging to achieve both efficiency and biocompatibility in a single nanoplatform. Polydopamine is known to preserve universal coating, metal-binding ability and multiphoton luminescence. Recently, it has been found to be a potential T1 MR contrast agent with the introduction of Fe3+. Herein, we utilized this property combined with FePt NPs, which intrinsically preserve computed tomography (CT), MRI T2-weighted effect and multiphoton contrast, and have successfully synthesized a four in one (T1, T2, CT, Optical) imaging system, FePt@mSiO2@PDA-PEG. It shows great magnetic resonance imaging efficiency (R1=3.502 mM-1S-1, R2=7.173 mM-1S-1) and strong computed tomography signal (CT) alike. In vitro and in vivo experiments have also been studied in this report. Furthermore, its biodegrading process is further explored and compared with different core/shell composition/structure (e.g. Fe3O4/nonporous SiO2). Drug releasing and photothermal therapy of FePt@mSiO2@PDA-PEG are also demonstrated to have great therapeutic potential. In summary, we have successfully designed a system with great multiple imaging efficiency and therapeutic potential, and is a promising candidate for theranostic agent.